OKYO
Okyo Pharma·NASDAQ
--
--(--)
--
--(--)
OKYO fundamentals
During H1 2026, Okyo Pharma (OKYO) reported revenue of --, a YoY change of 0.00%. Net income was -2.59M, a YoY change of 3.47%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2016 | FY,2017 | FY,2018 | FY,2019 | H1,2020 | FY,2020 | H1,2021 | FY,2021 | H1,2022 | FY,2022 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | H1,2026 | TTM |
|---|
Start Date | -- | -- | -- | Apr 1, 2018 | Apr 1, 2019 | Apr 1, 2019 | Apr 1, 2020 | Apr 1, 2020 | Apr 1, 2021 | Apr 1, 2021 | Apr 1, 2022 | Apr 1, 2023 | Apr 1, 2023 | Apr 1, 2024 | Apr 1, 2024 | Apr 1, 2025 | -- |
End Date | Mar 31, 2016 | Mar 31, 2017 | Mar 31, 2018 | Mar 31, 2019 | Sep 30, 2019 | Mar 31, 2020 | Sep 30, 2020 | Mar 31, 2021 | Sep 30, 2021 | Mar 31, 2022 | Mar 31, 2023 | Sep 30, 2023 | Mar 31, 2024 | Sep 30, 2024 | Mar 31, 2025 | Sep 30, 2025 | -- |
Fiscal Year-End | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | Mar 31 | -- |
Revenue | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Operating Expenses | -- -- | -- -- | -- -- | 4.57M -- | 1.04M -- | 1.53M -66.42% | 555.45K -46.67% | 3.37M +119.35% | 2.73M +392.23% | 6.22M +84.71% | 13.19M +112.10% | 8.73M -- | 15.75M +19.43% | 3.34M -61.77% | 7.09M -54.97% | 2.50M -25.07% | 6.25M -- |
Selling, General and Administrative Expenses | -- -- | -- -- | -- -- | 1.51M -- | 683.31K -- | -- -- | 517.83K -24.22% | -- -- | 2.25M +335.36% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Research and Development Expenses | -- -- | -- -- | -- -- | 3.06M -- | 358.22K -- | 518.10K -83.09% | 37.62K -89.50% | 348.35K -32.76% | 479.70K +1175.05% | 1.61M +362.06% | 6.34M +293.75% | 4.60M -- | 8.24M +30.07% | 2.22M -51.83% | 2.25M -72.65% | -44.05K -101.99% | -5.68K -- |
Other Operating Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | 1.02M -- | -- -- | 3.02M +196.87% | -- -- | 4.61M +52.69% | 6.85M +48.64% | 4.13M -- | 7.51M +9.59% | 1.12M -72.83% | 4.84M -35.55% | 2.55M +126.66% | 6.26M -- |
Operating Income | -- -- | -- -- | -- -- | -4.57M -- | -1.04M -- | -1.53M +66.42% | -555.45K +46.67% | -3.37M -119.35% | -2.73M -392.23% | -6.22M -84.71% | -13.19M -112.10% | -8.73M -- | -15.75M -19.43% | -3.34M +61.77% | -7.09M +54.97% | -2.50M +25.07% | -6.25M -- |
Non-Operating Income (Loss) | -- -- | -- -- | -- -- | -365.48K -- | -85.08K -- | -85.70K +76.55% | -69.61K +18.18% | -12.29K +85.65% | -1.02K +98.53% | 0 +100.00% | -96.69K -- | 0 -- | -1.05M -989.40% | -758.38K -- | -878.17K +16.63% | -84.58K +88.85% | -204.37K -- |
Other Non-Operating Income (Loss) | -- -- | -- -- | -- -- | -365.48K -- | -85.08K -- | -132.67K +63.70% | -69.10K +18.77% | -11.17K +91.58% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Interest Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -46.97K -- | 504 -- | 1.12K +102.39% | 1.02K +102.58% | 0 -100.00% | 96.69K -- | 0 -- | 1.05M +989.40% | 758.38K -- | 878.17K -16.63% | 84.58K -88.85% | 204.37K -- |
Interest Expense | -- -- | -- -- | -- -- | -- -- | -- -- | 1.16K -- | 504 -- | 1.12K -3.02% | 1.02K +102.58% | 0 -100.00% | 96.69K -- | 0 -- | 1.05M +989.40% | 758.38K -- | 883.65K -16.11% | 84.58K -88.85% | 209.84K -- |
Interest Income | -- -- | -- -- | -- -- | -- -- | -- -- | 48.13K -- | -- -- | 0 -100.00% | -- -- | 0 -- | 0 -- | -- -- | 0 -- | -- -- | 5.47K -- | -- -- | -- -- |
Pretax Income From Continuing Operations | -797.30K -- | -577.69K +27.54% | -28.29M -4797.50% | -4.94M +82.56% | -1.13M -- | -1.62M +67.17% | -625.05K +44.52% | -3.38M -108.50% | -2.74M -337.58% | -6.22M -84.03% | -13.28M -113.65% | -8.73M -- | -16.80M -26.49% | -4.10M +53.09% | -7.97M +52.57% | -2.59M +36.87% | -6.46M -- |
Income Tax Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -76.29K -- | 87 -- | -24.99K +67.24% | -188.76K -217066.67% | -786.52K -3046.84% | -12.20K +98.45% | 82.83K -- | 22.42K +283.71% | -1.42M -1811.74% | -3.26M -14660.04% | 52 +100.00% | -1.85M -- |
Current Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -76.29K -- | -- -- | -24.99K +67.24% | -- -- | -786.52K -3046.84% | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Deferred Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Income Tax Adjustments | -- -- | -- -- | -- -- | -- -- | -- -- | 1 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -797.30K -- | -577.69K +27.54% | -28.29M -4797.50% | -4.94M +82.56% | -1.13M -- | -1.54M +68.71% | -625.14K +44.51% | -3.35M -117.19% | -2.55M -307.32% | -5.43M -61.95% | -13.27M -144.37% | -8.82M -- | -16.83M -26.78% | -2.68M +69.61% | -4.71M +72.03% | -2.59M +3.47% | -4.61M -- |
Net Income Attributable to Owners of the Company | -- -- | -- -- | -- -- | -4.94M -- | -1.13M -- | -1.54M +68.71% | -625.14K +44.51% | -3.35M -117.19% | -2.55M -307.32% | -5.43M -61.95% | -13.27M -144.37% | -8.82M -- | -16.83M -26.78% | -2.68M +69.61% | -4.71M +72.03% | -2.59M +3.47% | -4.61M -- |
Net Income Attributable to Common Stockholders | -- -- | -- -- | -- -- | -4.94M -- | -1.13M -- | -1.54M +68.71% | -625.14K +44.51% | -3.35M -117.19% | -2.55M -307.32% | -5.43M -61.95% | -13.27M -144.37% | -8.82M -- | -16.83M -26.78% | -2.68M +69.61% | -4.71M +72.03% | -2.59M +3.47% | -4.61M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | -289.25K -- | -10.21K -- | 86.65K +129.96% | 12.48K +222.16% | 346.37K +299.71% | 37.84K +203.27% | -837.15K -341.70% | -441.01K +47.32% | 341.57K -- | 141.09K +131.99% | -480.49K -240.67% | -158.97K -212.67% | -331.01K +31.11% | -9.49K -- |
Total Comprehensive Income | -- -- | -- -- | -- -- | -5.22M -- | -1.14M -- | -1.46M +72.10% | -612.66K +46.11% | -3.01M -106.34% | -2.51M -309.44% | -6.27M -108.44% | -13.71M -118.77% | -8.48M -- | -16.68M -21.67% | -3.16M +62.71% | -4.87M +70.84% | -2.92M +7.67% | -4.62M -- |
Total Comprehensive Income Attributable to Owners of the Company | -- -- | -- -- | -- -- | -5.22M -- | -1.14M -- | -1.46M +72.10% | -612.66K +46.11% | -3.01M -106.34% | -2.51M -309.44% | -6.27M -108.44% | -13.71M -118.77% | -8.48M -- | -16.68M -21.67% | -3.16M +62.71% | -4.87M +70.84% | -2.92M +7.67% | -4.62M -- |
Basic EPS | -- -- | -- -- | -- -- | -0.01 -- | 0 -- | 0 +100.00% | 0 -- | -0.32 -- | 0 -- | -0.36 -12.50% | -0.61 -69.44% | -0.27 -- | -0.57 +6.56% | -0.08 +70.37% | -0.2 +64.91% | -0.07 +12.50% | -0.19 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -0.32 -- | -- -- | -0.36 -12.50% | -0.61 -69.44% | -0.27 -- | -0.57 +6.56% | -0.08 +70.37% | -0.2 +64.91% | -0.07 +12.50% | -0.19 -- |
Diluted EPS | 0 -- | 0 -- | -0.06 -- | -0.01 +83.33% | 0 -- | 0 +100.00% | 0 -- | -0.32 -- | 0 -- | -0.36 -12.50% | -0.61 -69.44% | -0.27 -- | -0.57 +6.56% | -0.08 +70.37% | -0.2 +64.91% | -0.07 +12.50% | -0.19 -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -0.32 -- | -- -- | -0.36 -12.50% | -0.61 -69.44% | -0.27 -- | -0.57 +6.56% | -0.08 +70.37% | -0.2 +64.91% | -0.07 +12.50% | -0.19 -- |
You can ask Aime
What were the key takeaways from Okyo Pharma’s earnings call?What factors drove the changes in Okyo Pharma's revenue and profit?What does Okyo Pharma do and what are its main business segments?What is the market's earnings forecast for Okyo Pharma next quarter?What is Okyo Pharma's gross profit margin?What were the key takeaways from Okyo Pharma's earnings call?What is Okyo Pharma's latest dividend and current dividend yield?What guidance did Okyo Pharma's management provide for the next earnings period?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
